Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: Dosimetric analysis and immunologic response

Clinical Cancer Research

Volumn 11, Issue 19 II, 2005, Pages

  Brouwers, Adrienne H ^a,c   Buijs, Wilhelmina C A M ^a   Mulders, Peter F A ^a   De Mulder, Pieter H M ^a   Van Den Broek, Wim J M ^a   Mala, Carola ^b   Oosterwijk, Egbert ^a   Boerman, Otto C ^a   Corstens, Frans H M ^a   Oyen, Wim J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Wilex Biotechnology GmbH   (Germany)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G250; HYBRID PROTEIN; RADIOACTIVE IODINE;

ADULT; AGED; ANTIBODY RESPONSE; BONE MARROW TOXICITY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DOSIMETRY; FEMALE; HUMAN; IMMUNOSCINTIGRAPHY; ISOTOPE LABELING; KIDNEY CARCINOMA; MALE; METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; ARTICLE; CHEMISTRY; DISEASE COURSE; KIDNEY TUMOR; KINETICS; METHODOLOGY; MIDDLE AGED; RADIATION RESPONSE; RADIOMETRY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; IODINE RADIOISOTOPES; KIDNEY NEOPLASMS; KINETICS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RADIOIMMUNOTHERAPY; RADIOMETRY; RECOMBINANT FUSION PROTEINS;

EID: 26444449997     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1004-0010     Document Type: Conference Paper

References (48)

1. Incidence of cancer in the Netherlands 1998. In: Visser O, Coebergh JWW, Schouten LJ, van Dijck JAAM, editors. Utrecht (the Netherlands): Vereniging van Integrale Kankercentra; 2002.
2. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
3. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993;20:303-21.
4. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1272-8.
5. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6:55-7s.
6. Savage PD. Renal cell carcinoma. Curr Opin Oncol 1996;8:247-51.
7. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997;15:1529-37.
8. 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999;5:3268-74s.
9. Oosterwijk E, Bander NH, Divgi CR, et al. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 1993;11:738-50.
10. Divgi CR, Bander NH, Scott AM, et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998;4:2729-39.
11. Behr TM, Sharkey RM, Juweid ME, et al. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med 1997;38:858-70.
12. Behr TM, Liersch T, Greiner-Bechert L, et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 2002;94:1373-81.
13. Ychou M, Pelegrin A, Faurous P, et al. Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab′)2 in patients with non-resectable liver metastases from colorectal cancer. Int J Cancer 1998;75:615-9.
14. Steffens MG, Oosterwijk-Wakka JC, Zegwaart-Hagemeier NE, et al. Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250. Anticancer Res 1999;19:1197-200.
15. Steffens MG, Boerman OC, Oyen WJ, et al. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy. Cancer Res 1999;59:1615-9.
16. 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 2004;45:1412-21.
17. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002;43:693-713.
18. 1311-cG250 in patients with metastasized clear cell renal cell carcinoma. In press: J Clin Oncol 2005.
19. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986;38:489-94.
20. Pastorek J, Pastorekova S, Callebaut I, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994; 9:2877-88.
21. Opavsky R, Pastorekova S, Zelnik V, et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 1996;33:480-7.
22. Grabmaier K, Vissers JL, De Weijert MC, et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 2000;85:865-70.
23. Uemura H, Nakagawa Y, Yoshida K, et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 1999;81:741-6.
24. Pastorekova S, Parkkila S, Parkkila AK, et al. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997;112:398-408.
25. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA, Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72:77-89.
26. Ebert T, Bander NH, Finstad CL, Ramsawak RD, Old LJ. Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res 1990;50:5531-6.
27. Uemura H, Okajima E, Debruyne FM, Oosterwijk E. Internal image anti-idiotype antibodies related to renal-cell carcinoma-associated antigen G250. Int J Cancer 1994;56:609-14.
28. Boerman OC, van Niekerk CC, Makkink K, Hanselaar TG, Kenemans P, Poels LG. Comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens. Int J Gynecol Pathol 1991;10:15-25.
29. Schrijvers AH, Quak JJ, Uyterlinde AM, et al. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res 1993;53:4383-90.
30. Buijs WC, Massuger LF, Claessens RA, Kenemans P, Corstens FH. Dosimetric evaluation of immunoscintigraphy using indium-111-labeled monoclonal antibody fragments in patients with ovarian cancer. J Nucl Med 1992;33:1113-20.
31. Buijs WC, Siegel JA, Boerman OC, Corstens FH. Absolute organ activity estimated by five different methods of background correction. J Nucl Med 1998; 39:2167-72.
32. 111In: an intrapatient comparison. Clin Cancer Res 2003;9:3953-60s.
33. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37:538-46.
34. Shen S, Meredith RF, Duan J, Brezovich IA, Khazaeli MB, LoBuglio AF. Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy. Cancer Biother Radiopharm 2003;18:209-15.
35. Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalint radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 2001;39:181-94.
36. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphoma. J Clin Oncol 2000;18:1316-23.
37. Juweid ME, Zhang CH, Blumenthal RD, Hajjar G, Sharkey RM, Goldenberg DM. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies. J Nucl Med 1999;40:1609-16.
38. O'Donoghue JA, Baidoo N, Deland D, Welt S, Divgi CR, Sgouros G. Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy. Cancer Biother Radiopharm 2002; 17:435-43.
39. DeNardo GL, Juweid M, White CA, Wiseman GA, DeNardo SJ. Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. Crit Rev Oncol Hematol 2001;39:203-18.
40. DeNardo SJ, Williams LE, Leigh B, Wahl RL. Choosing an optimal radioimmunotherapy dose for clinical response. Cancer 2002;94:1275-86.
41. Koral KF, Francis IR, Kroll S, Zasadny KR, Kaminski MS, Wahl RL. Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy. Cancer 2002;94:1258-63.
42. Koral KF, Dewaraja Y, Clarke LA, et al. Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: preliminary report. Cancer Biother Radiopharm 2000;15:347-55.
43. Blumenthal RD, Alisauskas R, Juweid M, Sharkey RM, Goldenberg DM. Defining the optimal spacing between repeat radioantibody doses in experimental models: is there an accurate measurement for hematopoietic recovery? Cancer 1997;80:2624-35.
44. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med 1998; 39:14-20s.
45. Chatal JF, Saccavini JC, Gestin JF, et al. Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas. Cancer Res 1989;49:3087-94.
46. Wiseman GA, Scott AM, Lee F, Gansen DN, Hopkins W, Steinmetz S, et al. Chimeric G250 (cG250) monoclonal antibody phase I dose escalation trial in patients with advanced renal cell carcinoma (RCC). Proc Annu Meet Am Soc Clin Oncol 2001;20:275a.
47. Bleumer I, Knuth A, Oosterwijk E, et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 2004;90:985-90.
48. 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 2000;41:1999-2010.